Table 4. Hazard ratios (HRs) and 95% confidence intervals (CIs) of Parkinson’s disease (PD) per standard deviation increase in the concentrations of specific leukocytes, after adjustment for age, sex, country of birth, socio-economic status, and fasting status a prospective cohort analysis^*.

Cohort analysis of ALS
Overall	Person-years	No. of outcomes	HR (95% CI)
Lymphocyte, 109 cells/L	771,683	53	1.04 (0.88-1.23)
Monocyte, 109 cells/L	762,037	52	0.96 (0.71-1.31)
Neutrophil, 109 cells/L	329,136	25	0.93 (0.60-1.44)
Eosinophil, 109 cells/L	709,283	49	1.18 (1.01-1.39)
Men	Person-years	No. of outcomes	HR (95% CI)
Lymphocyte, 109 cells/L	320,934	26	1.00 (0.66-1.52)
Monocyte, 109 cells/L	316,660	25	0.96 (0.62-1.49)
Neutrophil, 109 cells/L	130,764	9	0.86 (0.38-1.97)
Eosinophil, 109 cells/L	295,661	24	0.93 (0.60-1.42)
Women	Person-years	No. of outcomes	HR (95% CI)
Lymphocyte, 109 cells/L	450,749	27	1.06 (0.89-1.26)
Monocyte, 109 cells/L	445,377	27	0.98 (0.63-1.52)
Neutrophil, 109 cells/L	198,371	16	0.96 (0.57-1.62)
Eosinophil, 109 cells/L	413,622	25	1.32 (1.12-1.55)
Cohort analysis of PD
Overall	Person-years	No. of outcomes	HR (95% CI)
Lymphocyte, 109 cells/L	598,755	306	0.74 (0.59-0.94)
Monocyte, 109 cells/L	590,977	297	0.97 (0.85-1.09)
Neutrophil, 109 cells/L	242,248	152	1.00 (0.84-1.19)
Eosinophil, 109 cells/L	549,074	284	0.97 (0.86-1.10)
Men	Person-years	No. of outcomes	HR (95% CI)
Lymphocyte, 109 cells/L	248,078	181	0.72 (0.54-0.98)
Monocyte, 109 cells/L	244,656	174	0.95 (0.81-1.11)
Neutrophil, 109 cells/L	95,603	87	0.88 (0.68-1.13)
Eosinophil, 109 cells/L	228,092	170	0.94 (0.80-1.10)
Women	Person-years	No. of outcomes	HR (95% CI)
Lymphocyte, 109 cells/L	350,676	125	0.78 (0.54-1.11)
Monocyte, 109 cells/L	346,320	123	0.99 (0.81-1.21)
Neutrophil, 109 cells/L	146,644	65	1.14 (0.91-1.43)
Eosinophil, 109 cells/L	320,981	114	1.02 (0.84-1.24)

^*Bolded HRs are statistically significant with a P value of <0.05.